Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 58c, Beats on Revenue; Offers FY24 Revenue Guidance

Go back to Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 58c, Beats on Revenue; Offers FY24 Revenue Guidance

Castle Biosciences (CSTL) PT Raised to $35 at BTIG

August 6, 2024 7:31 AM EDT

BTIG analyst Sung Ji Nam raised the price target on Castle Biosciences (NASDAQ: CSTL) to $35.00 (from $32.00) while maintaining a Buy rating.

The analyst comments "Shares of CSTL are up 12% in the pre-market following a strong 25% Q2 revenue beat and raise to its... More